CN105288166A - 一种用于甲状腺肿大的中药组合物及其制备方法 - Google Patents
一种用于甲状腺肿大的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN105288166A CN105288166A CN201510871231.4A CN201510871231A CN105288166A CN 105288166 A CN105288166 A CN 105288166A CN 201510871231 A CN201510871231 A CN 201510871231A CN 105288166 A CN105288166 A CN 105288166A
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- chinese medicine
- medicine
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 99
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 210000001685 thyroid gland Anatomy 0.000 title description 29
- 239000000203 mixture Substances 0.000 title description 11
- 206010018498 Goitre Diseases 0.000 claims abstract description 40
- 201000003872 goiter Diseases 0.000 claims abstract description 39
- 238000002347 injection Methods 0.000 claims abstract description 17
- 239000007924 injection Substances 0.000 claims abstract description 17
- 239000009636 Huang Qi Substances 0.000 claims abstract description 16
- 239000002775 capsule Substances 0.000 claims abstract description 8
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 8
- 239000008187 granular material Substances 0.000 claims abstract description 6
- 239000006187 pill Substances 0.000 claims abstract description 3
- 239000003826 tablet Substances 0.000 claims abstract description 3
- 238000011282 treatment Methods 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 239000009806 pulsatillae Substances 0.000 claims description 21
- 241000756943 Codonopsis Species 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 14
- 210000000582 semen Anatomy 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 13
- 229920002472 Starch Polymers 0.000 claims description 12
- 239000008107 starch Substances 0.000 claims description 12
- 235000019698 starch Nutrition 0.000 claims description 12
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 11
- 239000000796 flavoring agent Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 238000004140 cleaning Methods 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 239000000470 constituent Substances 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000001506 calcium phosphate Substances 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 238000005138 cryopreservation Methods 0.000 claims description 4
- -1 hydroxypropyl Chemical group 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 239000008400 supply water Substances 0.000 claims description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 4
- 238000000108 ultra-filtration Methods 0.000 claims description 4
- 239000008215 water for injection Substances 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 229920003081 Povidone K 30 Polymers 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 2
- 239000003708 ampul Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 239000007767 bonding agent Substances 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 230000009969 flowable effect Effects 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 238000005374 membrane filtration Methods 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 239000012982 microporous membrane Substances 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000012744 reinforcing agent Substances 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 239000002002 slurry Substances 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 2
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 54
- 229940079593 drug Drugs 0.000 abstract description 14
- 239000000463 material Substances 0.000 abstract description 5
- 244000144730 Amygdalus persica Species 0.000 abstract description 3
- 241000092665 Atractylodes macrocephala Species 0.000 abstract description 2
- 235000006753 Platycodon grandiflorum Nutrition 0.000 abstract description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 2
- 241000007126 Codonopsis pilosula Species 0.000 abstract 1
- 241000234653 Cyperus Species 0.000 abstract 1
- 241000237502 Ostreidae Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 244000274050 Platycodon grandiflorum Species 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 244000179560 Prunella vulgaris Species 0.000 abstract 1
- 235000010674 Prunella vulgaris Nutrition 0.000 abstract 1
- 241000206469 Pulsatilla Species 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 230000000313 effect on goiter Effects 0.000 abstract 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 abstract 1
- 239000010931 gold Substances 0.000 abstract 1
- 229910052737 gold Inorganic materials 0.000 abstract 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 abstract 1
- 229960005375 lutein Drugs 0.000 abstract 1
- 235000020636 oyster Nutrition 0.000 abstract 1
- 239000008262 pumice Substances 0.000 abstract 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 abstract 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 abstract 1
- 235000008210 xanthophylls Nutrition 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 32
- 210000004369 blood Anatomy 0.000 description 31
- 238000000034 method Methods 0.000 description 25
- 208000002193 Pain Diseases 0.000 description 23
- 230000036407 pain Effects 0.000 description 23
- 210000004185 liver Anatomy 0.000 description 22
- 230000006870 function Effects 0.000 description 21
- 210000000952 spleen Anatomy 0.000 description 17
- 210000004072 lung Anatomy 0.000 description 14
- 206010011224 Cough Diseases 0.000 description 13
- 230000007812 deficiency Effects 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 230000017531 blood circulation Effects 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 206010062717 Increased upper airway secretion Diseases 0.000 description 10
- 235000009508 confectionery Nutrition 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 229930182470 glycoside Natural products 0.000 description 10
- 208000026435 phlegm Diseases 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 9
- 238000003304 gavage Methods 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 229930182490 saponin Natural products 0.000 description 9
- 235000017709 saponins Nutrition 0.000 description 9
- 210000001015 abdomen Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 150000007949 saponins Chemical class 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 150000002338 glycosides Chemical class 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 7
- 235000015099 wheat brans Nutrition 0.000 description 7
- APTNOIWSCDBIAS-UHFFFAOYSA-N 5,10,11-trihydroxy-9,9-bis(hydroxymethyl)-2,2,6a,6b,12a-pentamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound C1C(O)C(O)C(CO)(CO)C2CCC3(C)C4(C)CC(O)C5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C APTNOIWSCDBIAS-UHFFFAOYSA-N 0.000 description 6
- 206010000077 Abdominal mass Diseases 0.000 description 6
- 201000000736 Amenorrhea Diseases 0.000 description 6
- 206010001928 Amenorrhoea Diseases 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 231100000540 amenorrhea Toxicity 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- 201000007227 lymph node tuberculosis Diseases 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 208000005171 Dysmenorrhea Diseases 0.000 description 5
- 206010013935 Dysmenorrhoea Diseases 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 208000024770 Thyroid neoplasm Diseases 0.000 description 5
- 208000000260 Warts Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 201000010153 skin papilloma Diseases 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- KUBGFNFNLFGTGA-UHFFFAOYSA-N 4',5-Dimethyl-5-azaspiro[bicyclo[2.2.2]octane-2,2'-oxane]-6'-one Chemical compound C1C(C)CC(=O)OC21C(CN1C)CCC1C2 KUBGFNFNLFGTGA-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 4
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 206010033557 Palpitations Diseases 0.000 description 4
- 241000756042 Polygonatum Species 0.000 description 4
- 102000011923 Thyrotropin Human genes 0.000 description 4
- 108010061174 Thyrotropin Proteins 0.000 description 4
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 4
- KGGGRGBDMBZXKF-UHFFFAOYSA-N Virganreagenin G Natural products C1C(O)C(O)C(C)(CO)C2CCC3(C)C4(C)CC(O)C5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C KGGGRGBDMBZXKF-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 4
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 230000003325 follicular Effects 0.000 description 4
- 230000000762 glandular Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 201000003453 lung abscess Diseases 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- RNYZJZKPGHQTJR-UHFFFAOYSA-N protoanemonin Chemical compound C=C1OC(=O)C=C1 RNYZJZKPGHQTJR-UHFFFAOYSA-N 0.000 description 4
- 235000021251 pulses Nutrition 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 206010040872 skin infection Diseases 0.000 description 4
- 230000009747 swallowing Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 3
- NIGUICNPKCJLJQ-UHFFFAOYSA-N 9,10-Dihydro-2,3,5,7-Phenanthrenetetrol Chemical compound OC1=C(O)C=C2C3=C(O)C=C(O)C=C3CCC2=C1 NIGUICNPKCJLJQ-UHFFFAOYSA-N 0.000 description 3
- 206010003011 Appendicitis Diseases 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 description 3
- 206010010726 Conjunctival oedema Diseases 0.000 description 3
- 206010011732 Cyst Diseases 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 208000001204 Hashimoto Disease Diseases 0.000 description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 208000019255 Menstrual disease Diseases 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 241000037831 Polygonatum sibiricum Species 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 241000218201 Ranunculaceae Species 0.000 description 3
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 241000130764 Tinea Species 0.000 description 3
- 208000002474 Tinea Diseases 0.000 description 3
- 230000000954 anitussive effect Effects 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 239000006286 aqueous extract Substances 0.000 description 3
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 208000034158 bleeding Diseases 0.000 description 3
- 231100000319 bleeding Toxicity 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 description 3
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 208000031513 cyst Diseases 0.000 description 3
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 3
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 208000001780 epistaxis Diseases 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 206010029410 night sweats Diseases 0.000 description 3
- 230000036565 night sweats Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- GWBIYORWNUYYMZ-UHFFFAOYSA-N platycodin D Natural products CC1OC(OC2C(O)C(O)COC2OC(=O)C34CCC(C)(C)CC3C5=CCC6C7(C)CC(O)C(OC8CC(CO)C(O)C(O)C8O)C(CO)(CO)C7CCC6(C)C5(C)CC4O)C(O)C(O)C1OC9OCC(O)C(OC%10OCC(O)(CO)C%10O)C9O GWBIYORWNUYYMZ-UHFFFAOYSA-N 0.000 description 3
- CYBWUNOAQPMRBA-NDTOZIJESA-N platycodin D Chemical group O([C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2C1(CO)CO)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CYBWUNOAQPMRBA-NDTOZIJESA-N 0.000 description 3
- 229930185936 platycogenic acid Natural products 0.000 description 3
- 229930194443 polygalin Natural products 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 235000007686 potassium Nutrition 0.000 description 3
- 230000001047 pyretic effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000013076 thyroid tumor Diseases 0.000 description 3
- XWMMEBCFHUKHEX-MRTCRTFGSA-N (+)-Taraxasterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC[C@H]2[C@@H]3[C@H](C)C(=C)CC[C@]3(C)CC[C@]21C XWMMEBCFHUKHEX-MRTCRTFGSA-N 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 2
- YSCJAYPKBYRXEZ-HZPINHDXSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-4,4,6a,6b,11,11,14b-heptamethyl-8a-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3-hydroxy-4-[(2s,3r,4s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YSCJAYPKBYRXEZ-HZPINHDXSA-N 0.000 description 2
- QMKPCZNFLUQTJZ-UHFFFAOYSA-N (4aR)-10c-Hydroxy-1t.2c.4ar.6at.6bc.9.9.12ac-octamethyl-(8atH.12btH.14acH.14btH)-docosahydro-picen Natural products CC1CCC2(C)CCC3(C)C(CCC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C QMKPCZNFLUQTJZ-UHFFFAOYSA-N 0.000 description 2
- BAHMQESJBKGPTE-UHFFFAOYSA-N 1,5,8-trimethyl-3a,4-dihydroazuleno[6,5-b]furan-2,6-dione Chemical compound C1C2OC(=O)C(C)=C2C=C2C(C)=CC(=O)C2=C1C BAHMQESJBKGPTE-UHFFFAOYSA-N 0.000 description 2
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- JLUQTCXCAFSSLD-NXEZZACHSA-N Anemonin Chemical compound C1=CC(=O)O[C@]11[C@@]2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-NXEZZACHSA-N 0.000 description 2
- JLUQTCXCAFSSLD-UHFFFAOYSA-N Anemonin Natural products C1=CC(=O)OC11C2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000255789 Bombyx mori Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 2
- 239000003390 Chinese drug Substances 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000205426 Persicaria filiformis Species 0.000 description 2
- 235000016838 Pomo dAdamo Nutrition 0.000 description 2
- 244000003138 Pomo dAdamo Species 0.000 description 2
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 2
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 2
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 102000009843 Thyroglobulin Human genes 0.000 description 2
- 108010034949 Thyroglobulin Proteins 0.000 description 2
- 206010043706 Thyroid cyst Diseases 0.000 description 2
- 208000024799 Thyroid disease Diseases 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 2
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 2
- 235000000431 campesterol Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- ZGEFAWWFLHUTII-UHFFFAOYSA-N catalpin Natural products C1C(C23)(O)COC3OC(O)CC2C1OC(=O)C1=CC=C(O)C=C1 ZGEFAWWFLHUTII-UHFFFAOYSA-N 0.000 description 2
- ZGEFAWWFLHUTII-ZNOBHYIQSA-N chembl2332347 Chemical compound O([C@H]1[C@@H]2C[C@H](O[C@@H]3OC[C@]([C@H]23)(O)C1)O)C(=O)C1=CC=C(O)C=C1 ZGEFAWWFLHUTII-ZNOBHYIQSA-N 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 229940108928 copper Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 208000003532 hypothyroidism Diseases 0.000 description 2
- 230000002989 hypothyroidism Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000001055 magnesium Nutrition 0.000 description 2
- 229940091250 magnesium supplement Drugs 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- NGFFRJBGMSPDMS-UHFFFAOYSA-N psi-Taraxasterol Natural products CC12CCC(O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)C(C)=CCC3(C)CCC21C NGFFRJBGMSPDMS-UHFFFAOYSA-N 0.000 description 2
- 229930191447 pulchinenoside Natural products 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 2
- 229940032091 stigmasterol Drugs 0.000 description 2
- 235000016831 stigmasterol Nutrition 0.000 description 2
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 2
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 2
- 235000021286 stilbenes Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- HUTYZQWCTWWXND-NCTFTGAASA-N taraxasterol Natural products C[C@H]1[C@H]2C3=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)C[C@H](O)[C@@]2(C)CCC1=C HUTYZQWCTWWXND-NCTFTGAASA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 229960002175 thyroglobulin Drugs 0.000 description 2
- 208000021510 thyroid gland disease Diseases 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 230000002747 voluntary effect Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- SWMBOMMGMHMOHE-QQLCCCKISA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SWMBOMMGMHMOHE-QQLCCCKISA-N 0.000 description 1
- VELYAQRXBJLJAK-XKKWFBPMSA-N (2s,3r,4s,5s,6r)-2-[[(1s,4ar,5r,7s,7as)-5,7-dihydroxy-7-methyl-4a,5,6,7a-tetrahydro-1h-cyclopenta[c]pyran-1-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O([C@@H]1OC=C[C@H]2[C@H](O)C[C@@]([C@@H]12)(O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VELYAQRXBJLJAK-XKKWFBPMSA-N 0.000 description 1
- YDZWHGJRWMQCDP-NKILCQAGSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3-hydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-[(2s,3r,4 Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YDZWHGJRWMQCDP-NKILCQAGSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CNHZRRBWLMSLDX-WNHLAMKZSA-N 2''O-acetylplatycodin D Chemical compound O([C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2C1(CO)CO)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CNHZRRBWLMSLDX-WNHLAMKZSA-N 0.000 description 1
- JALVTHFTYRPDMB-UHFFFAOYSA-N 22(R),25(S)-demissidine Natural products C1CC2CC(O)CCC2(C)C2C1C1CC3N4CC(C)CCC4C(C)C3C1(C)CC2 JALVTHFTYRPDMB-UHFFFAOYSA-N 0.000 description 1
- HPVWWHYNAAZHQR-UHFFFAOYSA-N 3-O-beta-D-glucopyranosyl platycodigenin Natural products CC1(C)CCC2(C(O)CC3(C)C(=CCC4C5(C)CC(O)C(OC6OC(CO)C(O)C(O)C6O)C(CO)(CO)C5CCC34C)C2C1)C(=O)O HPVWWHYNAAZHQR-UHFFFAOYSA-N 0.000 description 1
- BKTRGHKZQSHBHT-UHFFFAOYSA-N 3-Oxobetulinic acid Natural products CC(=C)C1CCC2(CC3(C)C(CCC4C5(C)CCC(=O)C(C)(C)C5CCC34C)C12)C(=O)O BKTRGHKZQSHBHT-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- MWNRQKCSZFAAGI-UHFFFAOYSA-N 4,6-dihydroxy-2-O-(4'-hydroxybutyl)acetophenone Natural products CC(=O)c1c(O)cc(O)cc1OCCCCO MWNRQKCSZFAAGI-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- DYSOIAQEKRDXRB-GFTCARDDSA-N 8-Epidiosbulbin E acetate Chemical compound CC(=O)O[C@H]1C[C@@H]2C(=O)O[C@@H](C[C@@]2(C)[C@@H]2C[C@@H]3C[C@H]([C@@H]12)C(=O)O3)c1ccoc1 DYSOIAQEKRDXRB-GFTCARDDSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241001290610 Abildgaardia Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000011446 Amygdalus persica Nutrition 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 102100027308 Apoptosis regulator BAX Human genes 0.000 description 1
- 108050006685 Apoptosis regulator BAX Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 240000004435 Asplenium nidus Species 0.000 description 1
- 235000014256 Asplenium nidus Nutrition 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- SLJTWDNVZKIDAU-SVAFSPIFSA-N Betulonic acid Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C SLJTWDNVZKIDAU-SVAFSPIFSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000722721 Capparis Species 0.000 description 1
- 241000459479 Capsula Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010010510 Congenital hypothyroidism Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000299680 Cynanchum otophyllum Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 229930187095 Deapio-platycodin Natural products 0.000 description 1
- JALVTHFTYRPDMB-HRRTYWNUSA-N Demissidine Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H]3N4C[C@@H](C)CC[C@@H]4[C@@H](C)[C@@H]3[C@@]2(C)CC1 JALVTHFTYRPDMB-HRRTYWNUSA-N 0.000 description 1
- JALVTHFTYRPDMB-LKSVICNMSA-N Demissidine Natural products O[C@@H]1C[C@H]2[C@@](C)([C@H]3[C@@H]([C@H]4[C@@](C)([C@H]5[C@H](C)[C@@H]6N([C@H]5C4)C[C@@H](C)CC6)CC3)CC2)CC1 JALVTHFTYRPDMB-LKSVICNMSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- ZUORJPZGFYNDHW-UHFFFAOYSA-N Diosbulbin Natural products CC12C3CC4(OC(CC4C1CC5CC2C(=O)O5)c6cocc6)C(=O)O3 ZUORJPZGFYNDHW-UHFFFAOYSA-N 0.000 description 1
- OPNWTAMLIMDKEY-QGILWXNYSA-N Diosbulbin A Chemical compound C=1([C@@H]2OC34C[C@H](OC4=O)[C@H]4[C@H]([C@@]3(C2)C)C[C@@H](O)C[C@H]4C(=O)OC)C=COC=1 OPNWTAMLIMDKEY-QGILWXNYSA-N 0.000 description 1
- QEANLIISUSNNDX-YHPVUIEZSA-N Diosbulbin B Chemical compound C=1([C@H]2C[C@@]3([C@@]4(C(O[C@@H](C4)[C@H]4[C@H]3C[C@@H]3C[C@H]4C(O3)=O)=O)O2)C)C=COC=1 QEANLIISUSNNDX-YHPVUIEZSA-N 0.000 description 1
- OPNWTAMLIMDKEY-UHFFFAOYSA-N Diosbulbin-A Natural products COC(=O)C1CC(O)CC(C2(C3)C)C1C(OC1=O)CC21OC3C=1C=COC=1 OPNWTAMLIMDKEY-UHFFFAOYSA-N 0.000 description 1
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 1
- KYELXPJVGNZIGC-UHFFFAOYSA-N Ebeiensine Natural products C1C(=O)C2CC(O)CCC2(C)C(CC2=C3C)C1C2CCC13OC2CC(C)CNC2C1C KYELXPJVGNZIGC-UHFFFAOYSA-N 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 1
- 101150064015 FAS gene Proteins 0.000 description 1
- 102000015212 Fas Ligand Protein Human genes 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 241000202721 Guihaia Species 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- OVHUAFPHYGFWPY-UHFFFAOYSA-N Imperialin Natural products CC1CN2CC3C(CCC4C3CC5C4CC(=O)C6CC(O)CCC56C)CC2C(C)(O)C1 OVHUAFPHYGFWPY-UHFFFAOYSA-N 0.000 description 1
- IQDIERHFZVCNRZ-LZOOXBQUSA-N Imperialine Natural products O=C1[C@@H]2[C@@](C)([C@@H]3[C@H]([C@@H]4[C@H]([C@H]5[C@H]([C@@](O)(C)[C@H]6N(C[C@@H](C)CC6)C5)CC4)C3)C1)CC[C@@H](O)C2 IQDIERHFZVCNRZ-LZOOXBQUSA-N 0.000 description 1
- 206010067997 Iodine deficiency Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 241000885743 Melastoma dodecandrum Species 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- HMMCOAQTWLRBMU-WANIKOBHSA-N O1CC(C)CC[C@@]11C(=C)[C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CCCCC5CC[C@H]4[C@@H]3C[C@@H]2O1 Chemical compound O1CC(C)CC[C@@]11C(=C)[C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CCCCC5CC[C@H]4[C@@H]3C[C@@H]2O1 HMMCOAQTWLRBMU-WANIKOBHSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241000237509 Patinopecten sp. Species 0.000 description 1
- KYELXPJVGNZIGC-GKFGJCLESA-N Peimisine Chemical compound C([C@@H]1C(=O)C2)[C@@H](O)CC[C@]1(C)[C@@H](CC1=C3C)[C@@H]2[C@@H]1CC[C@@]13O[C@@H]2C[C@H](C)CN[C@H]2[C@H]1C KYELXPJVGNZIGC-GKFGJCLESA-N 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 240000003582 Platycodon grandiflorus Species 0.000 description 1
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 240000002381 Prunus davidiana Species 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- 206010062104 Renal mass Diseases 0.000 description 1
- 240000007994 Rhodomyrtus tomentosa Species 0.000 description 1
- 235000007234 Rhodomyrtus tomentosa Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- QMQIQBOGXYYATH-IDABPMKMSA-N Ruscogenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)[C@H](O)C[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 QMQIQBOGXYYATH-IDABPMKMSA-N 0.000 description 1
- BSUPFYRQXCQGLJ-UHFFFAOYSA-N Ruscogenin Natural products CC1CCC2(OC1)OC3C(O)C4C5CC=C6CC(O)CC(O)C6(C)C5CCC4(C)C3C2C BSUPFYRQXCQGLJ-UHFFFAOYSA-N 0.000 description 1
- 241000630329 Scomberesox saurus saurus Species 0.000 description 1
- OTWKACNCVAYEGM-UHFFFAOYSA-N Sibiricoside A Chemical compound O1C2CC3C4CC=C5CC(OC6C(C(O)C(OC7C(C(OC8C(C(O)C(O)CO8)O)C(O)C(CO)O7)OC7C(C(O)C(O)C(CO)O7)O)C(CO)O6)O)CCC5(C)C4CCC3(C)C2C(C)C1(OC)CCC(C)COC1OC(CO)C(O)C(O)C1O OTWKACNCVAYEGM-UHFFFAOYSA-N 0.000 description 1
- IQDIERHFZVCNRZ-LRCDAWNTSA-N Sipeimine Chemical compound C([C@@H]1C(=O)C[C@H]2[C@@H]3CC[C@H]4[C@]5(C)O)[C@@H](O)CC[C@]1(C)[C@H]2C[C@H]3[C@@H]4CN1[C@H]5CC[C@H](C)C1 IQDIERHFZVCNRZ-LRCDAWNTSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 101710119418 Superoxide dismutase [Mn] Proteins 0.000 description 1
- 101710202572 Superoxide dismutase [Mn], mitochondrial Proteins 0.000 description 1
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000009453 Thyroid Nodule Diseases 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 206010043782 Thyroiditis fibrous chronic Diseases 0.000 description 1
- 206010043784 Thyroiditis subacute Diseases 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- FSLPMRQHCOLESF-UHFFFAOYSA-N alpha-amyrenol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C FSLPMRQHCOLESF-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000001716 anti-fugal effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- RJWJHRPNHPHBRN-FKVJWERZSA-N aucubin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(CO)=C[C@@H](O)[C@@H]2C=CO1 RJWJHRPNHPHBRN-FKVJWERZSA-N 0.000 description 1
- UTDFQMAXCUGNJR-UHFFFAOYSA-N aucubin Natural products OCC1OC(Oc2ccoc2C3C(O)CCC3O)C(O)C(O)C1O UTDFQMAXCUGNJR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- JFSHUTJDVKUMTJ-QHPUVITPSA-N beta-amyrin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C JFSHUTJDVKUMTJ-QHPUVITPSA-N 0.000 description 1
- QQFMRPIKDLHLKB-UHFFFAOYSA-N beta-amyrin Natural products CC1C2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C)CCC1(C)C QQFMRPIKDLHLKB-UHFFFAOYSA-N 0.000 description 1
- PDNLMONKODEGSE-UHFFFAOYSA-N beta-amyrin acetate Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC23C)C1(C)C PDNLMONKODEGSE-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000020426 cherry syrup Nutrition 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 210000003685 cricoid cartilage Anatomy 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- WTYGAUXICFETTC-UHFFFAOYSA-N cyclobarbital Chemical compound C=1CCCCC=1C1(CC)C(=O)NC(=O)NC1=O WTYGAUXICFETTC-UHFFFAOYSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- QEANLIISUSNNDX-UHFFFAOYSA-N diosbulbin B Natural products O1C2(C(OC(C2)C2C3CC4CC2C(O4)=O)=O)C3(C)CC1C=1C=COC=1 QEANLIISUSNNDX-UHFFFAOYSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 201000008496 endemic goiter Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- QMQIQBOGXYYATH-UHFFFAOYSA-N epiruscogenin Natural products CC1C(C2(CCC3C4(C)C(O)CC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 QMQIQBOGXYYATH-UHFFFAOYSA-N 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004345 fruit ripening Effects 0.000 description 1
- 208000027692 gas pain Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- XTLWNMXYCHABQH-UHFFFAOYSA-N germanicol Natural products CC1(C)CCC2(C)CCC3(C)C(CCC4(C)C5(C)CCC(O)C(C)(C)C5CCC34C)C2=C1 XTLWNMXYCHABQH-UHFFFAOYSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000003823 hyoid bone Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- HIDAYMRWVVNXAO-UHFFFAOYSA-N imperialone Natural products CC1(O)C2CCC3C4CC(=O)C5CC(=O)CCC5(C)C4CC3C2CN2C1CCC(C)C2 HIDAYMRWVVNXAO-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 201000007772 internal hemorrhoid Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 235000006479 iodine deficiency Nutrition 0.000 description 1
- 230000001983 lactogenic effect Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- NNYVBULCQQMSLP-UHFFFAOYSA-N melittoside Natural products OCC1OC(OC2=C3C(=CC(O)C3(OC4OC(CO)C(O)C(O)C4O)C=CO2)CO)C(O)C(O)C1O NNYVBULCQQMSLP-UHFFFAOYSA-N 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- LXXMAYBNDHTYHL-UHFFFAOYSA-N methyl platyconate-A Natural products OC1CC(C2C(C3(CC(O)C4(CCC(C)(C)CC4C3=CC2)C(=O)OC2C(C(O)C(O)CO2)OC2C(C(O)C(OC3C(C(OC4C(C(O)(CO)CO4)O)C(O)CO3)O)C(C)O2)O)C)(C)CC2)(C)C2C(C(=O)OC)(CO)C1OC1OC(CO)C(O)C(O)C1O LXXMAYBNDHTYHL-UHFFFAOYSA-N 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- WVHRUHMGDQLMBZ-NQZYIAJFSA-N monomelittoside Natural products O([C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1OC=C[C@]2(O)[C@H](O)C=C(CO)[C@@H]12 WVHRUHMGDQLMBZ-NQZYIAJFSA-N 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- VELYAQRXBJLJAK-UHFFFAOYSA-N myoporoside Natural products C12C(C)(O)CC(O)C2C=COC1OC1OC(CO)C(O)C(O)C1O VELYAQRXBJLJAK-UHFFFAOYSA-N 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- MTKRZWWQDYNZRK-UHFFFAOYSA-N phenanthrene-1,2,3,4-tetrol Chemical compound C1=CC=C2C3=C(O)C(O)=C(O)C(O)=C3C=CC2=C1 MTKRZWWQDYNZRK-UHFFFAOYSA-N 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229930189407 platycodin Natural products 0.000 description 1
- IVDSKBGNLNNRFN-UHFFFAOYSA-N platycodin A Natural products CC1OC(OC2C(O)C(O)COC2OC(=O)C34CCC(C)(C)CC3C5=CCC6C7(C)CC(O)C(OC8CC(CO)C(O)C(O)C8O)C(CO)(CO)C7CCC6(C)C5(C)CC4O)C(OC(=O)C)C(O)C1OC9OCC(O)C(OC%10OCC(O)(CO)C%10O)C9O IVDSKBGNLNNRFN-UHFFFAOYSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229940109990 ruscogenin Drugs 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 235000020637 scallop Nutrition 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 201000007497 subacute thyroiditis Diseases 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 201000006489 suppurative thyroiditis Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- GGGUGZHBAOMSFJ-GADYQYKKSA-N taraxerol Chemical compound CC([C@@H]1CC2)(C)[C@@H](O)CC[C@]1(C)[C@@H]1[C@]2(C)C2=CC[C@@]3(C)CCC(C)(C)C[C@H]3[C@]2(C)CC1 GGGUGZHBAOMSFJ-GADYQYKKSA-N 0.000 description 1
- HYTFUKZLSYXRDX-UHFFFAOYSA-N taraxerol Natural products CC1CCCC2C3(C)CCC4(C)C5CC(C)(C)CCC5(C)C=CC4(C)C3C(O)CC12C HYTFUKZLSYXRDX-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000000534 thyroid cartilage Anatomy 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
一种用于甲状腺肿大的中药及其制备方法,属于药物制备的技术领域。本发明的中药组成为:夏枯草、蒲公英、黄芪、党参、白术、茯苓、白芍、牡蛎、桔梗、桃仁、赤芍、川贝、海浮石、黄药子、生地、香附、七星剑、桃金娘、白头翁、黄精和桂枝。上述中药各组分经炮制、清洗、干燥后加入医学上可接受的辅料以制备成汤剂、片剂、颗粒剂、散剂、水针剂、胶囊剂或蜜丸。上述各味药制成的药物对于甲状腺肿大有很好的治愈效果,副作用小。
Description
技术领域
本发明公开一种成本低的用于甲状腺肿大的中药组合物及其制备方法,属于药物制备的技术领域。
背景技术
辐射是心血管病、糖尿病、癌突变的主要诱因;2、辐射易对人体生殖系统、神经系统、免疫系统造成伤害;3、辐射是孕妇流产、不育、畸胎等病变的诱发因素;4辐射直接影响儿童的发育、骨髓发育,导致视力下降、视网膜脱落、肝脏造血功能下降;5辐射可使性功能下降,女性内分泌紊乱,月经失调。
甲状腺就位于“喉结”的下方约2~3厘米处,在吞咽东西时可随其上下移动。甲状腺形如“H”,棕红色,分左右两个侧叶,中间以峡部相连。两侧叶贴附在喉下部和气管上部的外侧面,上达甲状软骨中部,下抵第六气管软骨处,峡部多位于第二至第四气管软骨的前方,有的人不发达。有时自峡部向上伸出一个锥状叶,长短不一,长者可达舌骨,为胚胎发育的遗迹,常随年龄而逐渐退化,故儿童较成年人为多。
甲状腺外覆有纤维囊,称甲状腺被囊,此囊伸入腺组织将腺体分成大小不等的小叶,囊外包有颈深筋膜(气管前层),在甲状腺侧叶与环状软骨之间常有韧带样的结缔组织相连接,故吞咽时,甲状腺可随吞咽而上下移动。甲状腺激素的生理功能主要为:(1)促进新陈代谢,使绝大多数组织耗氧量加大,并增加产热。(2)促进生长发育,对长骨、脑和生殖器官的发育生长至关重要,尤其是婴儿期。此时缺乏甲状腺激素则会患呆小症。(3)提高中枢神经系统的兴奋性。此外,还有加强和调控其它激素的作用及加快心率、加强心缩力和加大心输出量等作用。
甲状腺由许多滤泡组成。显微镜下所见:滤泡由单纯的立方腺上皮细胞环绕而成,中心为滤泡腔。腺上皮细胞是甲状腺激素合成和释放的部位,滤泡腔内充满均匀的胶性物质,是甲状腺激素复合物,也是甲状腺激素的贮存库。滤泡形态学的改变可反映腺体功能状态:腺体活动减弱时,腺上皮细胞呈扁平状,滤泡腔内贮存物增加;如果活动亢进,腺泡上皮呈柱状,滤泡腔内贮存物减少。
甲状腺肿是指良性甲状腺上皮细胞过度增生形成的甲状腺肿,是甲状腺疾病最常见的临床表现。近年来,本病的发病率和诊断率不断攀升。甲状腺肿疾病严重时会压迫周围器官,容易引起饮食和呼吸困难。目前,对该病的治疗方法一般采用手术治疗,然而手术后往往会出现甲状腺功能的衰退,甚至会留下永久的疤痕。临床医生常用左旋甲状腺素治疗甲状腺肿,但疗效慢、疗程长,效果不明显。
甲状腺疾病包括:单纯性甲状腺肿;甲状腺功能亢进(甲状腺功能亢进的并发症);甲状腺功能减退、甲状腺结节、甲状腺瘤;急性化脓性甲状腺炎;亚急性甲状腺炎;慢性淋巴细胞性甲状腺炎(桥本甲状腺炎);慢性纤维性甲状腺炎甲状腺肿俗称“粗脖子”、“大脖子”或“瘿脖子”。以缺碘为主的代偿性甲状腺肿大,青年女性多见,一般不伴有甲状腺功能异常,散发性甲状腺肿可有多种病因导致相似结果,即机体对甲状腺激素需求增加,或甲状腺激素生成障碍,人体处于相对或绝对的甲状腺激素不足状态,血清促甲状腺激素(TSH)分泌增加,只有甲状腺组织增生肥大。现有甲状腺肿的药物的副作用较大,有的效果不够好。
发明内容
本发明的目的就是针对现有治疗甲状腺肿药物有的副作用较大,有的效果不够好之不足,而提供一种治疗成本低、安全无毒副作用,且见效快的用于甲状腺肿大的中药。
上述用于甲状腺肿大的中药由夏枯草、蒲公英、黄芪、党参、白术、茯苓、白芍、牡蛎、桔梗、桃仁、赤芍、川贝母、海浮石、黄药子、生地,香附、七星剑、桃金娘、白头翁、黄精和桂枝配伍制成。
上述用于甲状腺肿大的中药中各味中药的重量份组成为:夏枯草2~9份、蒲公英11~35份、黄芪9~28份、党参35~45份、白术11~25份、茯苓3~19份、白芍2~11份、牡蛎5~30份、桔梗8~25份、桃仁12~30份、赤芍5~25份、川贝母6~30份、海浮石6~30份、黄药子5~19份、生地6~27份、香附3~20份、七星剑7~25份、桃金娘11~30份、白头翁12~28份、黄精5~18份和桂枝12~28份。
具体地,上述用于甲状腺肿大的中药中各味中药的重量份组成为:夏枯草7份、蒲公英25份、黄芪17份、党参40份、白术20份、茯苓15份、白芍7份、牡蛎25份、桔梗20份、桃仁20份、赤芍18份、川贝母20份、海浮石18份、黄药子12份、生地20份、香附15份、七星剑20份、桃金娘20份、白头翁24份、黄精12份和桂枝20份。
具体地,上述用于甲状腺肿大的中药中各味中药的重量份组成为:夏枯草6份、蒲公英18份、黄芪15份、党参40份、白术18份、茯苓12份、白芍8份、牡蛎22份、桔梗18份、桃仁18份、赤芍18份、川贝母25份、海浮石20份、黄药子15份、生地22份、香附15份、七星剑18份、桃金娘20份、白头翁18份、黄精12份和桂枝18份。
夏枯草别名:麦穗夏枯草、铁线夏枯草、麦夏枯、铁线夏枯、夕句、乃东(本经)等。味辛、苦,性寒。归肝、胆经。功效:清热泻火,明目,散结消肿。应用:1.目赤肿痛、头痛眩晕、目珠夜痛。本品苦寒主入肝经,善泻肝火以明目。2.瘰疬、瘿瘤。常配贝母、香附等药用以治肝郁化火,痰火凝聚之瘰疬。夏枯草的化学成分:三萜皂苷、芸香苷、金丝桃苷等苷类物质及熊果酸、咖啡酸、游离齐敦果酸等有机酸。夏枯草经水浸出液、乙醇-水浸出液及乙醇浸出液均可明显降低实验动物血压。现代临床用以治疗高血压病,有助降压;取其散结消肿而常用治甲状腺肿大、淋巴结肿大、乳腺增生、高血压等属于肝热者。夏枯草配伍当归、白芍夏枯草清肝散淤;当归、白芍养血补血。三者伍用有解肝郁、养肝血之功效用于治疗肝郁血虚所致诸症。
夏枯草的炮制方法:夏枯草晒干即可。
上述蒲公英富含维生素A、维生素C及钾,也含有铁、钙、维生素B2、维生素B1、镁、维生素B6、叶酸及铜、蛋白质、碳水化合物。蒲公英植物体中含有蒲公英醇、蒲公英素、胆碱、有机酸、菊糖等多种健康营养成分。蒲公英性味甘,微苦,寒。归肝、胃经。有利尿、缓泻、退黄疸、利胆等功效。治热毒、痈肿、疮疡、内痈、目赤肿痛、湿热、黄疸、小便淋沥涩痛、疔疮肿毒,乳痈,瘰疬,牙痛,目赤,咽痛,肺痈,肠痈,湿热黄疸,热淋涩痛。急性结膜炎,感冒发热,急性扁桃体炎,急性支气管炎,胃炎,肝炎,胆囊炎,尿路感染等。功能主治:清热解毒,利尿散结。蒲公英全草含蒲公英甾醇、胆碱、菊糖、果胶等。根中含蒲公英醇、蒲公英赛醇、ψ-葡公英甾醇、蒲公英甾醇、β-香树脂醇、豆甾醇、β-谷甾醇、胆碱、有机酸、果糖、蔗糖、葡萄糖、葡萄糖甙以及树脂、橡胶等。药理作用:⑴抗菌作用:该品注射液试管内对金黄色葡萄球菌耐药菌株、溶血性链球菌有较强的杀菌作用。对肺炎双球菌、脑膜炎球菌、白喉杆菌、绿脓杆菌、痢疾杆菌、伤寒杆菌等及卡他球菌也有一定杀菌作用。⑵通乳:该品叶有疏通乳脉管之阻塞,促进泌乳的作用。⑶抗肿瘤作用。⑷利胆作用。
蒲公英的炮制方法:新鲜的蒲公英阴干后捣汁。
黄芪又名绵芪。黄芪性甘温,归肺经,有补气升阳、益卫固表之功能。现代医学研究表明,黄芪有增强机体免疫功能、保肝、利尿、抗衰老、抗应激、降压和较广泛的抗菌作用。黄芪不仅能扩张冠状动脉,改善心肌供血,提高免疫功能,而且能够延缓细胞衰老的进程。药用价值:1、表虚自汗:多用于体虚表弱所致的自汗;2、阴虚盗汗;3、急性肾炎水肿:用于阳气不足所致的虚性水肿;4、慢性肾炎水肿、脾肾虚;5、阳气虚弱:用于疮疡久不溃破而内陷,有促进溃破及局限作用;6、疮疡溃破:久不收口,有生肌收口之作用;7、肺气虚证:咳喘日久,气短神疲,痰雍于肺无力咯出;8、气虚衰弱:倦怠乏力,或中气下陷、脱肛、子宫脱垂。性味:甘,微温。归经:归肺、脾、肝、肾经。
黄芪的炮制方法:采用炒黄芪,取黄芪片置锅内,用文火炒至深黄色微有焦斑,取出放凉。
党参味甘,性平。有补中益气、止渴、健脾益肺,养血生津。用于脾肺气虚,食少倦怠,咳嗽虚喘,气血不足,面色萎黄,心悸气短,津伤口渴,内热消渴。
党参的炮制方法:采用麸炒党参,先以武火将锅加热,撒入麸皮,候冒烟时,倒入党参片,拌炒至表面呈微黄色,取出,筛去麸皮,放凉。党参每100kg,加入麸皮20kg。
白术拉丁学名Atractylodesmacrocephala。别名桴蓟,于术,冬白术,淅术,杨桴,吴术,片术、苍术等,属于菊科、苍术属多年生草本植物。味苦,甘,性温。归脾、胃经。功能主治:健脾益气,燥湿利水,止汗,安胎。用于脾虚食少,腹胀泄泻,痰饮眩悸,水肿,自汗,胎动不安。土白术健脾,和胃,安胎。用于脾虚食少,泄泻便溏,胎动不安。药理作用:1、利尿作用:具有明显而持久的利尿作用。2、降血糖作用:家兔灌胃煎剂或浸膏,血糖稍有降低。3、强壮作用:白术煎剂灌胃1mol或6g/kg,能促进小鼠体重增加和增强游泳耐力,白术能增强网状内皮系统的吞噬功能;白术还能提高淋巴细胞转化率和自然玫瑰花形成率,促进细胞免疫功能,且IgG明显增高。说明白术有健脾胃、壮身体和提高抗病能力的作用。4、抗凝血作用:白术对血小板聚集有明显的抑制作用,白术煎剂0.5g/kg灌胃1~4周,能显着延长大鼠凝血酶元的时间。5、白术有血管扩张作用。6、抗肿瘤作用:体外试验表明,白术挥发油中之中性油对食管癌细胞有明显抑制作用。7、抗菌作用:水浸液在试管内对絮状表皮癣菌、星形奴卡氏菌有抑制作用。8、促进造血功能。9、促进蛋白质合成:白术煎剂10g/kg灌胃,连续7天,明显促进小鼠小肠蛋白质的合成等。
炮制方法:挖掘白术的根部、剪去茎秆、逐渐烘干使得表面水分低于1%。取原药,除去杂质,大小分开,洗净、闷润透,切厚片,晒干或低温干燥,过筛。
茯苓味甘、淡,性平。归经归心、肺、脾、肾经。功效利水渗湿,健脾,宁心。
炮制方法:取原药材,浸泡、洗净。润透,稍蒸热切厚片或块,干燥。
白芍正名为青羊参Cynanchumotophyllum。白芍为毛茛科植物芍药PaeoniatactiloraPall.的干燥根。夏、秋二季采挖,洗净,除去头尾和细根,置沸水中煮后除去外皮或去皮后再煮,晒干。具有养血调经,敛阴止汗,柔肝止痛,平抑肝阳之功效。常用于血虚萎黄,月经不调,自汗,盗汗,胁痛,腹痛,四肢挛痛,头痛眩晕。
炮制方法:取白芍片置锅内,用文火加热,炒至表面微黄色,取出放凉。
牡蛎药材全年可采收,将牡蛎去肉、洗净,晒干可得。其性微寒,味咸;有重镇安神,潜阳补阴,软坚散结的功效;可治疗惊悸失眠,眩晕耳鸣,自汗盗汗,遗精崩带,胃痛吞酸等病症。性味归经:咸,微寒;归肝、胆、肾经。功能:平肝息风药;养阴药。痰核,瘰疬,瘿瘤,症瘕积聚。该品味咸,软坚散结。用治痰火郁结之痰核,瘰疬,瘿瘤等。
炮制方法:采用煅牡蛎,取净牡蛎,置无烟的炉火上或适宜的容器中,用武火加热,煅至酥脆时取出,放凉,碾碎。
桔梗(Platycodongrandiflorus),别名包袱花、铃铛花、僧帽花,是多年生草本植物,茎高20~120厘米,通常无毛,偶密被短毛,不分枝,极少上部分枝。叶全部轮生,部分轮生至全部互生,无柄或有极短的柄,叶片卵形,卵状椭圆形至披针形,叶子卵形或卵状披针形,花暗蓝色或暗紫白色,可作观赏花卉;其根可入药,有止咳祛痰、宣肺、排脓等作用。药理作用:1、祛痰与镇咳作用;桔梗所含皂甙口服时对咽喉粘膜及胃粘膜造成某种程度的刺激,反射地引起呼吸道粘膜分泌亢进,使痰液稀释,促使其排出,粗制桔梗皂甙有镇咳作用。2、降血糖作用:兔灌胃桔梗水或醇提取物200mg/kg可使血糖下降水和醇提取物500mg/kg连续4天灌胃,对实验性四氧嘧啶糖尿病兔亦有降血糖作用,降低的肝糖原在用药后也见恢复,且能抑制食物性血糖上升,醇提取物的作用较水提取物强。3、抗炎作用4、对循环系统的作用:大鼠以粗制桔梗皂甙静脉注射,可见暂时性血压下降,心率减慢和呼吸抑制。对离体豚鼠心耳,高浓度时呈负性肌力作用。5、抑制胃液分泌和抗溃疡作用。此外粗桔梗皂甙有镇静、镇痛和解热作用。能抑制小鼠自发性活动,延长环己巴比妥钠的睡眠时间。化学成份:根含多种皂甙,如桔梗皂甙(platycodin)A、C、D、D2、D3,去芹菜糖基桔梗皂甙(deapioplatycodin)D、D3、2-O-=乙酰基桔梗皂甙(2-O-acetylplatycodin)D2,3-O-乙酰基桔梗皂甙(3-O-acetylplaty-codin)D2,远志皂甙(polyglalacin)D、D2,2-O-乙酰基远志皂甙(2-O-acetylpolygalacin)D、D2,3-O-乙酰基远志皂甙(3-O-acetylpolygalacin)D、D2,桔梗甙酸-A甲酯(methylplatyconate-A),2-O-甲基桔梗甙酸-A甲酯(methyl-2-O-methyplatyconate-A),桔梗甙酸-A内酯(platyconicacid-Alactone),其中主成分是桔梗皂甙D,桔梗皂甙A又叫做2-O-乙酰基桔梗皂甙D,桔梗皂甙C又叫做3-O-乙酰基桔梗皂甙D。多种混合皂甙经完全水解所产生的皂甙元有:桔梗皂甙元(platycodigenin),远志酸(polygalacicacid),以及少量的桔梗酸(platycodigenin),远志酸(polygalacicacid),以及少量的桔梗酸(platycogenicacid)A、B、C等。
炮制方法:取桔梗片置锅内用火炒至表面微黄色。
桃仁为蔷薇科植物桃Prunuspersica(L.)Batsch或山桃Prunusdavidiana(Carr.)Franch.的干燥成熟种子。果实成熟后采收,除去果肉和核壳,取出种子,晒干。具有活血祛瘀,润肠通便,止咳平喘的功效。用于经闭痛经,瘕瘕痞块,肺痈肠痈,跌扑损伤,肠燥便秘,咳嗽气喘。性味:苦、甘,平。归经:归心、肝、大肠经。功效:活血祛瘀,润肠通便,止咳平喘。主治:用于经闭痛经,瘕瘕痞块,肺痈肠痈,跌扑损伤,肠燥便秘,咳嗽气喘。
炮制方法:麸炒桃仁,先将麸皮撒入锅内,待麸皮冒烟时,倒入燀桃仁,用文火炒至表面呈黄色,取出,筛去麸皮,放凉。桃仁每100Kg,用麸皮12kg。其中燀桃仁是取净桃仁置沸水中,加热至种皮微鼓起,捞出,在凉水中稍浸泡,取出搓开种皮与种仁,干燥,除去种仁。
赤芍为毛茛科植物赤芍或川赤芍的干燥根。春、秋二季采挖,除去根茎、须根及泥沙,晒干。苦,微寒。归肝经。有清热凉血,活血祛瘀的功效。性味味苦,性微寒。归经归肝经。功效清热凉血,散瘀止痛。主治:用于热人营血,温毒发斑,吐血衄血,目赤肿痛,肝郁胁痛,经闭痛经,瘾瘕腹痛,跌扑损伤,痈肿疮疡。
炮制方法:采用炒赤芍,取赤芍片置锅内,用文火加热,炒至颜色加深,偶有焦斑,取出放凉。
川贝母性凉,甘平;入肺经、胃经;功效:肺止咳化痰平喘,清热化痰。1、镇咳作用 2、川贝碱具有降压作用。3.抗菌作用。主治:用于肺虚、久咳、虚劳咳嗽、燥热咳嗽、干咳少痰、咯痰带血、肺痈、瘰疬、痈肿、乳痈。川贝母的鳞茎含有生物碱:川贝碱、西贝素、青贝碱、松贝碱、松贝乙素、贝母辛碱、垂茄次碱,还含有皂苷及钾、镁、钙、铁、铜、镉、锌、钠等金属元素。
炮制方法:清除泥沙后,不能淘洗,及时将鲜贝母阴干,不可堆放。烘干温度40~50℃。
浮海石一般是由铝、钾、钠的硅酸盐所成,亦即以SiOz为主要成分的类似玻璃组成的矿物。归经:肺;肾;肝;大肠经。消瘿顺气散。
浮海石经破碎、研磨成粉。
黄药子也叫朱砂七,此药为寥科植物金线草(Antenoronfiliforme)的全草。对各种类型的甲状腺肿,均有一定效果。主要成分:半干块茎含蔗糖、还原糖、淀粉、藻甙、鞣质.尚含黄独素B,C(DiosbulbinsB,C)与薯蓣皂甙元(Diosgenin)。野生的含黄独素A、B、C。含黄药子素(diosbulbin)A-H,8-表黄药子素E乙酸酯(8-epidiosbulbinEacetate)。薯蓣皂甙元(diosgenin),D-山梨糖醇(D-sorbitol),2,4,6,7-四羟基-9-10-二氢菲(2,4,6,7-tetrahydroxy-9,10-dihydrophenanthrene),2,4,5,6-
四羟基菲(2,4,5,6-tetrahydroxyphenantyhrene),4-羟基-(2-反-3',7'-dimethylocta-2',6'-辛二烯基)-6-甲氧基苯乙酮[4-hydroxy(2-trans-3',7'-
dimethylocta-2',6'-dienyl)-6-methoxyacetophenone],4,6-二羟基-2-O-(4'-羟丁基)苯乙酮[4,6-dihydroxy-2-O-(4'-hydroxybutyl)acetophenone],二氢薯蓣碱(dihydrodioscorine),蔗糖、还原糖、淀粉、皂甙、鞣质等。
炮制方法:取原药材,除去杂质,洗净,润透,切小块或厚片,干燥。
生地药理功效:(1)地黄既有止血作用,又有抗凝血作用。(2)抗真菌作用 地黄水浸剂对须疮癣菌、石膏样小芽胞癣菌、羊毛状小芽胞癣菌及奥杜盎小芽胞癣菌等多种真菌的生长有抑制作用。(3)对内分泌的影响生地黄具有对抗地塞米松对垂体-肾上腺皮质系统的抑制作用,并能促进肾上腺皮质激素的合成.性味归经:甘,寒。归心,肝,肾经。生地黄根茎主要含B-谷甾醇与甘露醇,及少量豆甾醇、微量的菜油甾醇(Campesterol),还含地黄素(Rehmannin)、生物碱、脂肪酸、梓醇(Catalpol)、葡萄糖与0.0053%的维生素A类物质;根又含水苏糖、4.2%精氨酸与3.O%r-丁氨酸。怀庆地黄的根茎也含甘露醇、水苏糖、0.11%的梓醇、蔗糖、4.2%精氨酸、3.O%r-丁氨酸。干地黄中分得糸列脂肪酸、β-谷甾醇、棕榈酸、丁二酸、胡萝卜甙及S8环状化合物。地上部分含monomelittoside,leonuride及桃叶珊瑚甙、梓醇甙、二氢梓醇甙。
炮制方法:干燥碾磨成粉末。
香附为莎草科植物莎草的干燥根茎。秋季采挖,燎去毛须,置沸水中略煮或蒸透后晒干,或燎后直接晒干。辛、微苦、微甘,平。归经:归肝、脾、三焦经。功效;疏肝解郁,理气宽中,调经止痛。主治:用于肝郁气滞,胸胁胀痛,疝气疼痛,乳房胀痛,脾胃气滞,脘腹痞闷,胀满疼痛,月经不调,经闭痛经。
炮制方法:采用四制香附,取净香附碎块或片,用姜汁、盐水、黄酒、米醋拌匀,闷透,置锅内用文火加热,炒干取出放凉。香附每100kg,用黄酒、米醋各10Kg、生姜5kg、食盐2Kg。
七星剑是一味中草药,主治:跌打损伤,扭伤,胸腹积伤,两胁打伤;外治腰脊强痛。根治风湿痉痛,腰部扭伤。别名:巢蕨,金桃叶(潮安)、七叶星(普宁)。小叶不红、假芥兰、星色草(《生草药性备要》),独行千里(《本草求原》),野香薷(《岭南草药志》),小叶荠薴(《广西植物名录》),(《生草药性备要》)。性味:味辛,性温,无毒。功效:内服祛风去积散气止痛;外用消肿止痛。
炮制方法:鲜品捣汁。
桃金娘别名:金丝桃、山稔子、山菍、多莲、豆稔干、稔果、多奶、山多奶、苏园子、石榴子、白碾子、岗稔、水刀莲、乌肚子等。桃金娘药味甘、涩,性平;归肝,脾经,归肺经;功能主治:养血止血;涩肠固精。主血虚体弱,吐血,鼻衄,劳伤咳血,便血,崩漏,遗精,带下,痢疾,脱肛,烫伤,外伤出血,收敛止血根含酚类、鞣质等,有治慢性痢疾、风湿、肝炎及降血脂等功效。叶:收敛止泻,止血。用于急性胃肠炎,消化不良,痢疾:外用治外伤出血。果:补血,滋养,安胎。用于贫血,病后体虚,神经衰弱,耳鸣,遗精。
炮制方法:洗净后、干燥粉碎即可。
白头翁为毛茛科白头翁植物白头翁的根。白头翁味苦、性寒;归胃、大肠经。白头翁具有1、抗氧化、抗炎:白头翁具有阻止肝组织中过氧化物的释放,增长MnSOD的活性,阻止乙型肝炎病毒的感染。龙盛京等利用鲁米诺发光体系,研究发现白头翁水提液具有较强的抗活性氧化作用,能有效清除过氧化氢,防止其所引起的脂质过氧化而造成细胞或组织损伤。张文远等研究发现白头翁醇提物对葡聚糖硫酸诱导的大鼠结肠炎具有明显的抑制作用。/2、杀虫、抑菌:兰继毓等研究发现白头翁煎剂对杀灭溶组织内阿米巴的效果较好。曹景花等用K-B纸片扩散法测得白头翁水提液对金黄色葡萄球菌、绿脓杆菌、炭疽杆菌、伤寒杆菌、甲型链球菌、乙型链球菌具有明显的抑制作用。功能主治:治疗痔疮等出血症状。治热毒血痢,温疟寒热,鼻衄,血痔。白头翁根含白头翁皂甙(pulchinenoside)A、B、C、D,3-O-α-L-吡喃鼠李糖-(1→2)-α-L-吡喃阿拉伯糖-3β,23-二羟基-△20(29)-羽扇豆烯-28-酸[3-O-α-L-rhamnopyranosyl-(1→2)-α-L-arabinopyranosyl-3β,23-
dihydroxylup△-20(29)-en-28-oicacid],白头翁皂甙(pulchinenoside)A3、B4,皂甙(saponin)1、2,白桦脂酸-3-O-α-L阿拉伯吡喃糖甙(betulinicacid-3-O-α-L-arabinopyranoside),白桦脂酸(betulinicacid),3-氧代白桦脂酸(3-oxobetulinicacid),胡萝卜甙(daucosterol),白头翁素(anemonin),原白头翁素(protoanemonin)。
炮制方法:取原药材,除去杂质、洗净、润透,切厚片,干燥。
黄精(学名:Polygonatumsibiricum),又名:鸡头黄精、黄鸡菜、笔管菜、爪子参、老虎姜、鸡爪参。为黄精属植物,根茎横走,圆柱状,结节膨大。叶轮生,无柄。药用植物,具有补脾,润肺生津的作用。黄精的根状茎含甾体皂甙,已分离出2个呋甾烯醇型皂甙和2个螺甾烯醇型皂甙。属于前者的是:26-O-β-D-吡喃葡萄糖基-22-O-甲基-(25)S-呋甾-5-烯-3β,26-二醇3-O-β-石蒜四糖甙(26-O-β-D-glucopyranosyl-22-O-methyl-25(S)-furost-5-ene-3β,26-diol3-O-β-lycotetraoside)即西伯利亚蓼甙A(sibiricoside-A)和26-O-β-D-吡喃葡萄糖基-22-O-甲基-25(S)-呋甾-5-烯-3β,14α,26-三醇3-O-β-石蒜四糖甙(26-O-β-D-glucopyranosyl-22-O-methyl-25(S)-fruost-5-ene-3β,14α,26-triol-3-O-β-lycotetraoside)即14α-羟基西伯利亚蓼甙A(14α-hydroxysibiricosideA);属于后者的是:(23S,25R)螺甾-5-烯-3β,14α,23-三醇3-O-β-lycotetraoside)即西伯利亚蓼甙B(sibiricosideB)和新巴拉次薯蓣皂甙元-A3-O-β-石蒜四糖甙(neoprazerigeninA3-O-β-lycotetraoside)。另含黄精多糖A、B、C,三者的相对分子质量均大于20万,均由葡萄糖(glucose)、甘露糖(mannose)和半乳糖醛酸(galacturonicacid)按照摩尔比6:26:1缩合而成;又含黄精低聚糖A、B、C,相对分子质量分别为1630、862和472,系由果糖(fructose)与葡萄糖按摩尔比8︰1.4︰1和2︰1缩合而成。1、抗病原微生物作用:体外试验表明、黄精水提出液(1︰320)对伤寒杆菌、金黄色葡萄球菌、抗酸杆菌有抑制作用。2、对血糖的影响:黄精浸膏对肾上腺素引起的血糖过高呈显着抑制作用。3、抗疲劳作用:黄精煎剂17.67%浓度0.3ml/只腹腔注射,可延长小鼠游泳时间。4、抗氧化作用:黄精煎液20%浓度,13ml/只喂饮,连续27天,使小鼠肝脏超氧化物歧化酶(SOD)活性升高,心肌脂褐质含量降低。5、延缓衰老作用:黄精煎剂,20%浓度浸泡桑叶喂养家蚕,有延长家蚕幼虫期的作用。6、止血作用。7、对心血管作用:黄精水浸膏0.16~0.26g/kg静脉注射,明显增加麻醉犬冠脉流量;1.5g/kg静脉注射,对垂体后叶素引起的兔心肌缺血有对抗作用,对抗垂体后叶素引起的T波增高,促进T波异常提前恢复;12g/kg腹腔注射,可增强小鼠对缺氧的耐受力。8、抗病毒作用:黄精多糖0.2%眼液滴眼,6次/天,或加服黄精多糖10mg/kg,2次/天,对兔实验性单纯疱疹病毒性角膜炎均有治疗作用。9、其它作用:黄精煎剂6g/kg灌胃,连续10天,可提高小鼠红细胞膜Na+,K+--ATP酶活性。
炮制方法:采用蒸黄精,洗净,置笼屉内,蒸至棕黑色滋润时,取出,切厚片。
桂枝是肉桂的干燥嫩枝,一般在春、夏季节采收,去除叶后直接晒干或切片晒干即可。桂枝辛温,可祛风寒,能治疗感冒风寒、发热恶寒等。其性味辛、甘,温,入肺、心、膀胱经,是主治里寒常用的温里药,具有补元阳、通血脉、暖脾胃之功效,常与补肝肾药、补气血药配伍,治疗肾阳不足、命门火衰、肢冷脉微,与其它温里药配伍治疗脘腹冷痛、寒痹腰痛,具有明显的镇痛和抗癌防癌的作用。功能:桂枝能发汗解肌,温经通脉,助阳化气,散寒止痛。主风寒表证;寒湿痹痛;四肢厥冷;经闭痛经;症瘕结块;胸痹;心悸;痰饮;小便不利。用于风寒感冒,脘腹冷痛,血寒经闭,关节痹痛,痰饮,水肿,心悸,奔豚。
炮制方法:炒桂枝,取净桂枝片或段,置锅内,用文火加热,炒至微显焦斑,取出放凉。
本发明的优点是:治疗甲状腺肿无副作用,治疗效果好,治愈快。
甲状腺囊肿肿块呈圆形,直径多在2~5厘米之间。光滑,一般不疼或轻微疼痛,随着吞咽上下移动。多数是单发结节,少见于多发结节。甲状腺囊内压不高时,质地较为柔软,如果液体较多,质地就会比较坚韧。患者没有明显感觉,通常是无意中发现颈前部肿物。检查上通常采用超声波检查,确诊是囊性还是结节,区分是薄壁还是厚壁囊肿。囊肿多为良性,甲状腺癌伴囊肿者少见。临床常规采用外科手术摘除,超声引导下穿刺治疗为主,但是效果往往不理想。甲状腺囊肿类似于中医学的“瘿痈”、“瘿瘤”、“结喉痛”。该病病机多为情志久郁不舒,加之素体气虚,卫表不固,风热邪毒乘虚入侵,热毒蕴结,气血壅滞,久则生成肝郁热蕴、痰气瘀结、瘿络瘀滞等证,故热、毒、瘀乃其病机之关键。
本发明药物具有软坚散结、活血化瘀等功效,对甲状腺肿患者治疗彻底,疗效好,无毒副作用,患者康复快,不易复发,而且治疗周期短,费用低,所选用中药原料药源丰富,便于推广应用。本发明的采用上述各味中药加以医学上可接受的辅料以制备成不同的剂型方便不同的患者服用。优选的不同剂型为汤剂、片剂、颗粒剂、散剂、针剂、胶囊剂以及蜜丸等。
具体地,上述医学上可接受的辅料为稀释剂包括但不限于山梨醇、甘露醇、淀粉、乳糖、粉状或微晶状纤维素、二钙磷酸盐,三钙磷酸盐或糖;填充剂:羧甲基纤维素钠、PVP-K30、羟丙基纤维素、淀粉浆、甲基纤维素、乙基纤维素、羟丙基甲基纤维素或胶化淀粉;崩解剂:干淀粉、交联聚维酮、交联羧甲基纤维素钠、羧甲基淀粉钠或低取代羟丙基纤维素;润滑剂:硬脂酸镁、滑石粉、十二烷基硫酸钠或微粉硅胶或结合剂、润滑剂、流动剂、复合形成剂、释放控制剂、膜衣剂、塑化剂、着色剂、调味剂、甜味剂、黏度增强剂、保存剂或抗氧化剂。
本发明所提供的药物组合物主要是适用于甲状腺肿大。
本发明所提供的药物组合物的组分经清洗后、不同的药物采用不同的炮制方法后,采取中药常规煎服方法,以汤剂的形式服用;其具体操作是以将上述药物组合物经清洗、干燥后,投入药物总重量的5~20倍蒸馏水中煎煮1~3次,每次煎煮时间为1~3h,收取每次煎煮后的药汁、经灭菌处理,袋装或瓶装分装,低温保存即得汤剂。
进一步地,本发明的药物组合物经清洗、不同的药物采用不同的炮制方法后,干燥后,采用30%~60%(wt%)乙醇萃取药物中的活性成分,萃取2~4次,每次萃取时间为30~60min,每次萃取采用乙醇的质量为原药物总重量的3~7倍,每次萃取的温度为40~70℃;收取上述乙醇得到的药汁,采用袋装或小瓶分装,灭菌处理后低温保存。采用乙醇萃取药物组合物中的活性成分,使得萃取得到的汤剂的药效更明显。
本发明的药物组合物经清洗、低温干燥后再经乙醇萃取后溶于注射水中,超声、搅拌使其完全溶解,加入注射用活性炭,在30~70℃水浴中保持20~30min,微孔过滤膜过滤,在用截留分子量为5万的超滤膜超滤,补足注射用水,分装于安瓿中,每支封口,灭菌即得水针剂。
进一步地,上述药物组合物经清洗、干燥后经乙醇萃取得出其中药物的活性成分,药物活性成分和甘露醇一起溶解于注射用水中,超声、搅拌使其完全溶解,然后加入注射用活性炭,30~70℃水浴中保持20~30min,趁热与微孔滤膜过滤,再用截留分子量为5万的超滤膜过滤,补足注射用水,分装于西林瓶中,每支装药物活性成分的溶液5ml和注射用水5~10ml,冷冻干燥中冻干,即得粉剂。
本发明的药物组合物经清洗、低温或室温下干燥后加入透明质酸钠、乳糖、微晶纤维素、聚维酮、硬脂酸镁,分别取上述药物组合物及辅料,分别粉碎;过300目筛,将透明质酸、药物组合物,乳糖、微晶纤维素混合均匀,以聚维酮的乙醇溶液为黏合剂制成软材,制粒、干燥、整粒,加入硬脂酸镁,混合均匀,压片、即得片剂。
进一步地,本发明的药物组合物经清洗、低温干燥后加入透明质酸钠、预胶化淀粉,分别取药物组合物及辅料,粉碎,过300目筛,混匀,均匀喷入蒸馏水,制软材,制粒、干燥、整粒,装入胶囊即得胶囊剂。
本发明的药物组合物经清洗、低温干燥后,使用机械将各药物进行粉碎,将粉碎后的药物过300目筛,然搅拌混合,最后包装得散剂。
具体地,采用上述不同方法制成不同剂型的同时加入矫味剂以改善药物的口味,使得其更容易被患者接受。矫味剂为:蔗糖、单糖浆、芳香糖浆以及甜菊苷、山梨醇、甘露醇,其中芳香糖浆为橙皮糖浆、枸橼糖浆、樱桃糖浆、甘草糖浆及桂皮糖浆等。
在具体服用本发明不同剂型得到的药物,以每次服用2~5g原药/次,每天1~3次,以10天为一个疗程,2~3个疗程为一个治疗期。每个疗程间间隔1~3天。对于甲状腺肿大的患者服用本发明的药物组合物的上述不同剂型,服用3个疗程即见效果,当继续服用3~7个疗程,病情基本得到控制,达到治本且治表的效果,同时不复发。
具体实施方式
1、动物模拟实验
结果表明:中药组具有显著降低EAT小鼠血清甲状腺球蛋白抗体(TGAb)、甲状腺过氧化酶抗体(TPOAb)的水平、改善甲状腺功能、减轻或修复受损甲状腺细胞结构的作用。
SPF级SD雌性大鼠90只、雌雄各半,体重为100~150g/只,适应性喂养一周,按体重层次随机取30只为正常对照组,剩余为造模组。第二周起造模组饮用高碘水浓度为350g/L,对照组予蒸馏水。第四周起造模组于双后足皮下多点注射由完全弗氏佐剂(CFA)充分乳化成油包水状的TG(TG︰CFA=1︰1),共两次,中间间隔两天,每次每只含TG100μg,作为初次免疫,第五周于后背皮下多点注射由弗氏不完全佐剂(IFA)乳化的TG,每次每只含100μg,每周一次,连续五周,作为加强免疫。第八周结束时成模。将成模后的大鼠随机分为模型对照组(20只)、西医治疗组1(10只)、西药治疗组2(10只)中药治疗组(20只)。软坚消瘿汤组每只大鼠灌胃量为10ml/kg/d。西药组予雷公藤多甙片,温开水配成悬浊液(2.37g/ml)等量灌胃。模型组及正常对照组灌服等量蒸馏水。四组均每天给药2次,连续5周。观察四组大鼠甲状腺组织Fas、FasL、BAX、BCL-2表达的影响。经几组实验得出:对照组无明显变化,西药组1和西药组2的小鼠甲状腺组织逐渐正常,但是所有小鼠都存在不同程度的消瘦、萎靡不振的现象、不活跃;然而采用本实验的中药组的大鼠甲状腺组织逐渐正常,大鼠也表现出原有的活力。
2、临床资料收治门诊患者170例,随机将患者分为两组,治疗组100例,给予本发明药物治疗,对照组35例,给予现有药物左旋甲状腺素治疗;对照组2采用放射性治疗。三组实验的患者性别、年龄和病情无显著差异,具有可比性。诊断标准全部病例均按甲状腺肿临床表现诊断标准确定诊断。治疗方法治疗方法是在病人自愿前提下,治疗组患者服用本发明药物的不同剂型,每日2次,剂量为原药3~5g/次,一般患者连续服用20~40天,中性患者连续服用1~3个月,严重患者连续服用4个月~8年。对照组1患者仍采用现有药物左旋甲状腺素进行长期治疗;对照组2采用服用碘-131。疗效评定标准(以临床症状消失为准)
治愈:临床症状消失,甲状腺大小正常,3个月未见复发。显效:临床症状消失,甲状腺肿块明显减小。
无效:甲状腺肿块未见明显变化。
甲状腺均肿大。
诊断标准:(1)弥漫性质地坚硬的甲状腺肿。(2)TgAb(甲状腺球蛋白抗体)和TmAb(甲状腺微粒体抗体)显著增高或伴有FT4(血清游离甲状腺素)、FT3(血清游离三碘甲腺原氨酸)降低。(3)甲状腺细针病理穿刺检查。经实验组和对照组观察得出:采用本发明的药物的不同剂型更容易被患者接受,口感舒适,由中药制成,无辐射和毒副作用的隐患。一般症状的患者经服用2~3疗程后,病症基本好转;而中性患者服用4各疗程便见明显疗效;对于重症患者连续服用7各疗程,病情也得到基本控制,经停药7天后再服用2个疗程,病情基本好转。相对而言,对照组服用碘-131,患者病情也得到明显好转,但患者心理压力大,随后也出现了肌肉无力,疼痛,胃不适等情况。
个别案例:
王女士,55岁,患者甲状腺I度肿大,心率85次/min,心慌不显,舌红、脉细数。甲状腺B超:双侧甲状腺肿大。甲功:TT3:1.28μg/mL,TT4:49.8μg/mL,TSH:10.81nIu/mL,FT3:3.08pg/mL,FT4:0.45ng/dL;TGAb:51.24u/mL,TPOAb:>1000.00u/mL。服用本发明治疗甲状腺肿大的中药组合物进行治疗,治疗2个疗程后,偶有咳嗽咳痰,痰少色白,无胸闷心慌,无恶寒发热,无潮热盗汗。复查甲功示:TMAb:226.54U/mL,舌偏红,脉细,继续服用4个疗程,痊愈。
张女士,35岁,颈前不适,心烦,乏力,食欲不振,排便不畅,2日一行。双侧甲状腺II度肿大,质软,无触痛。舌淡红、苔薄腻,脉细。甲状腺B超:双侧甲状腺弥漫性增大。甲功:TT3:1.32μg/mL,TT4:41.5ng/mL,TSH:38.45nIu/mL,FT3:2.18pg/mL,FT4:0.52ng/dL,TGAb:421.58u/mL,TPOAb:800.59u/mL。服用了本发明治疗桥本甲状腺炎的中药组合物,4个疗程后,甲状腺肿诸症均改善。复查甲状腺功能已恢复正常,TGAb及TPOAb有所下降。继续服用2个疗程,各指标恢复正常,病获痊愈。
陈先生,42岁,患者在体检中发现右侧甲状腺有明显增大,无不适反应。彩超显示右侧甲状腺实质内见两个大注分别为2.1×0.9cm、1.2×0.7cm的偏低回声结节,形态欠规则,边界清楚,内回声不均质,周边探及环状血流信号,内探及少许血流信号,左侧甲状腺实质内见一个大小约1.4×0.6cm的偏低回声结节,形态欠规则,边界清楚,内回声不均质,周边探及环状血流信号,内探及少许血流信号。后患者服用本发明中药制剂4个疗程,病情痊愈,未见复发。
本发明中药制剂所选药材配伍相宜,符合中医药和现代医药研究理论,并采用现代先进的医药制药技术制成不同剂型方便不同患者,同时改善药物的口感。上述药物具有育阴潜阳、豁痰散结、降逆和中的功效,适用于先天性甲状腺功能减退症与儿童及成人的各种原因引起的甲状腺功能减退症的长期治疗,有效率100%,治愈率高达95%。以上显示和描述了本发明的基本原理和主要特征和本发明的优点。本行业的技术人员应该了解,本发明不受上述实施例的限制,上述实施例和说明书中描述的只是说明本发明的原理,在不脱离本发明精神和范围的前提下,本发明还会有各种变化和改进,这些变化和改进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书及其等效物界定。
Claims (8)
1.一种用于甲状腺肿大的中药,其特征在于:其由夏枯草、蒲公英、黄芪、党参、白术、茯苓、白芍、牡蛎、桔梗、桃仁、赤芍、川贝、海浮石、黄药子、生地,香附、七星剑、桃金娘、白头翁、黄精和桂枝制成。
2.根据权利要求1所述的一种用于甲状腺肿大的中药,其特征在于:所述中药中各味中药的重量份组成为:夏枯草2~9份、蒲公英11~35份、黄芪9~28份、党参35~45份、白术11~25份、茯苓3~19份、白芍2~11份、牡蛎5~30份、桔梗8~25份、桃仁12~30份、赤芍5~25份、川贝6~30份、海浮石6~30份、黄药子5~19份、生地6~27份、香附3~20份、七星剑7~25份、桃金娘11~30份、白头翁12~28份、黄精5~18份和桂枝12~28份。
3.一种用于甲状腺肿大的中药加入医学上可接受的辅料以制备成汤剂、片剂、颗粒剂、散剂、水针剂、胶囊剂或蜜丸。
4.根据权利要求3所述的一种用于甲状腺肿大的中药,其特征在于:所述辅料为:稀释剂包括但不限于山梨醇、甘露醇、淀粉、乳糖、粉状或微晶状纤维素、二钙磷酸盐,三钙磷酸盐或糖;填充剂:羧甲基纤维素钠、PVP-K30、羟丙基纤维素、淀粉浆、甲基纤维素、乙基纤维素、羟丙基甲基纤维素或胶化淀粉;崩解剂:干淀粉、交联聚维酮、交联羧甲基纤维素钠、羧甲基淀粉钠或低取代羟丙基纤维素;润滑剂:硬脂酸镁、滑石粉、十二烷基硫酸钠或微粉硅胶或结合剂、润滑剂、流动剂、复合形成剂、释放控制剂、膜衣剂、塑化剂、着色剂、调味剂、甜味剂、黏度增强剂、保存剂或抗氧化剂。
5.根据权利要求3所述的一种用于甲状腺肿大的中药,其特征在于:所述中药汤剂的制备方法:
将夏枯草、蒲公英、黄芪、党参、白术、茯苓、白芍、牡蛎、桔梗、桃仁、赤芍、川贝、海浮石、黄药子、生地,香附、七星剑、桃金娘、白头翁、黄精和桂枝炮制后、药物经清洗、干燥后,投入药物总重量的5~20倍蒸馏水中煎煮1~3次,每次煎煮时间为1~3h,收取每次煎煮后的药汁、经灭菌处理,袋装或瓶装分装,低温保存即可。
6.根据权利要求3所述的一种用于甲状腺肿大的中药,其特征在于:所述中药汤剂的制备方法:
将夏枯草、蒲公英、黄芪、党参、白术、茯苓、白芍、牡蛎、桔梗、桃仁、赤芍、川贝、海浮石、黄药子、生地,香附、七星剑、桃金娘、白头翁、黄精和桂枝炮制后,干燥后,采用30%~60%(wt%)乙醇萃取药物中的活性成分,萃取2~4次,每次萃取时间为30~60min,每次萃取采用乙醇的质量为原药物总重量的3~7倍,每次萃取的温度为40~70℃;收取上述乙醇得到的药汁,采用袋装或小瓶分装,灭菌处理后低温保存。
7.根据权利要求3所述的一种用于甲状腺肿大的中药,其特征在于:所述中药水针剂的制备方法:将夏枯草、蒲公英、黄芪、党参、白术、茯苓、白芍、牡蛎、桔梗、桃仁、赤芍、川贝、海浮石、黄药子、生地,香附、七星剑、桃金娘、白头翁、黄精和桂枝炮制后,干经清洗、低温干燥后再经乙醇萃取后溶于注射水中,超声、搅拌使其完全溶解,加入注射用活性炭,在30~70℃水浴中保持20~30min,微孔过滤膜过滤,在用截留分子量为5万的超滤膜超滤,补足注射用水,分装于安瓿中,每支封口,灭菌即得水针剂。
8.根据权利要求3所述的一种用于甲状腺肿大的中药,其特征在于:所述中药粉剂的制备方法:
将夏枯草、蒲公英、黄芪、党参、白术、茯苓、白芍、牡蛎、桔梗、桃仁、赤芍、川贝、海浮石、黄药子、生地,香附、七星剑、桃金娘、白头翁、黄精和桂枝炮制后,经清洗、干燥后经乙醇萃取得出其中药物的活性成分,药物活性成分和甘露醇一起溶解于注射用水中,超声、搅拌使其完全溶解,然后加入注射用活性炭,30~70℃水浴中保持20~30min,趁热与微孔滤膜过滤,再用截留分子量为5万的超滤膜过滤,补足注射用水,分装于西林瓶中,每支装药物活性成分的溶液5ml和注射用水5~10ml,冷冻干燥中冻干,即得粉剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510871231.4A CN105288166A (zh) | 2015-12-02 | 2015-12-02 | 一种用于甲状腺肿大的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510871231.4A CN105288166A (zh) | 2015-12-02 | 2015-12-02 | 一种用于甲状腺肿大的中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105288166A true CN105288166A (zh) | 2016-02-03 |
Family
ID=55186444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510871231.4A Pending CN105288166A (zh) | 2015-12-02 | 2015-12-02 | 一种用于甲状腺肿大的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105288166A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106334155A (zh) * | 2016-08-08 | 2017-01-18 | 青岛友诚高新技术有限公司 | 一种治疗动甲状腺肿大的中药组合物及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62198621A (ja) * | 1986-02-24 | 1987-09-02 | Kanebo Ltd | 制癌補助剤 |
CN102698043A (zh) * | 2012-05-28 | 2012-10-03 | 孙立平 | 一种治疗甲状腺的药物组合物 |
CN102764315A (zh) * | 2012-08-01 | 2012-11-07 | 王颖 | 一种治疗甲状腺肿的药物 |
CN103223101A (zh) * | 2013-04-19 | 2013-07-31 | 张冠珍 | 一种治疗甲状腺囊肿的中药 |
CN104873624A (zh) * | 2015-06-02 | 2015-09-02 | 韦兴邦 | 一种用于痛风性关节炎的药物组合物 |
-
2015
- 2015-12-02 CN CN201510871231.4A patent/CN105288166A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62198621A (ja) * | 1986-02-24 | 1987-09-02 | Kanebo Ltd | 制癌補助剤 |
CN102698043A (zh) * | 2012-05-28 | 2012-10-03 | 孙立平 | 一种治疗甲状腺的药物组合物 |
CN102764315A (zh) * | 2012-08-01 | 2012-11-07 | 王颖 | 一种治疗甲状腺肿的药物 |
CN103223101A (zh) * | 2013-04-19 | 2013-07-31 | 张冠珍 | 一种治疗甲状腺囊肿的中药 |
CN104873624A (zh) * | 2015-06-02 | 2015-09-02 | 韦兴邦 | 一种用于痛风性关节炎的药物组合物 |
Non-Patent Citations (2)
Title |
---|
建康: "《中华养生食谱金方 卷2》", 30 June 2008, 北京燕山出版社 * |
钟山等: "《青年学生健康教育》", 31 July 2005, 广东高等教育出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106334155A (zh) * | 2016-08-08 | 2017-01-18 | 青岛友诚高新技术有限公司 | 一种治疗动甲状腺肿大的中药组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100404067C (zh) | 治疗儿童肺系疾病的中药制剂 | |
CN102784363B (zh) | 一种治疗胰腺癌的中药组合物及其制备方法 | |
CN102205107B (zh) | 一种治疗十二指肠溃疡的中药制剂及其制备方法 | |
CN101972338A (zh) | 一种治疗小儿上呼吸道感染的中药制剂及其制备方法 | |
CN102755596B (zh) | 一种治疗痰湿型乳腺增生的中药及制备方法 | |
CN103555530A (zh) | 百合保健药酒 | |
CN105232911A (zh) | 一种中药组合物 | |
CN104042891A (zh) | 缓解产妇大便秘结的中药组合物及其制备方法 | |
CN104873826A (zh) | 一种可清肺祛湿的茶饮及其制备方法 | |
CN103638475A (zh) | 一种治疗乳癖的中药喷雾剂及其制备方法 | |
CN103705860B (zh) | 一种治疗婴幼儿黄疸的中药组合物及其制备方法 | |
CN105435197A (zh) | 一种治疗桥本氏病的药物组合物及其制备方法 | |
CN105343593A (zh) | 一种降压降脂的夏枯草保健口服液及其制备方法 | |
CN105079676A (zh) | 一种治疗脂肪肝的药物及其制备方法 | |
CN104825821A (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN104162093A (zh) | 治疗乳腺癌的中药制剂及其制备方法 | |
CN107213360A (zh) | 一种治疗重型肌无力的中药组合物 | |
CN102178866A (zh) | 用于气郁、血瘀体质人袪湿活血、软坚散结的中药制剂及其制备方法和应用 | |
CN105288166A (zh) | 一种用于甲状腺肿大的中药组合物及其制备方法 | |
CN104984141A (zh) | 一种治疗便秘的方剂及其制备方法 | |
CN105853901A (zh) | 癌症病人放化疗期间服用的制剂及制法 | |
CN104758701A (zh) | 一种胃结石碎石后护理治疗的药物及其制备方法 | |
CN104547494A (zh) | 治疗甲亢的中药组合物药酒及制备工艺 | |
CN103007202A (zh) | 一种治疗胰腺癌的中药组合物 | |
CN103099886A (zh) | 有助于改善肠胃功能的软胶囊及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160203 |
|
RJ01 | Rejection of invention patent application after publication |